Rafferty Asset Management’s Avidity Biosciences RNAM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-81,533
| Closed | -$5.88M | – | 1132 |
|
|
2025
Q4 | $5.88M | Sell |
81,533
-91,947
| -53% | -$5.94M | 0.02% | 385 |
|
|
2025
Q3 | $7.56M | Buy |
173,480
+46,598
| +37% | +$1.88M | 0.02% | 345 |
|
|
2025
Q2 | $3.6M | Sell |
126,882
-17,935
| -12% | -$535K | 0.01% | 465 |
|
|
2025
Q1 | $4.27M | Sell |
144,817
-32,167
| -18% | -$1M | 0.02% | 403 |
|
|
2024
Q4 | $5.15M | Sell |
176,984
-22,381
| -11% | -$935K | 0.02% | 411 |
|
|
2024
Q3 | $9.16M | Buy |
199,365
+78,808
| +65% | +$3.42M | 0.03% | 298 |
|
|
2024
Q2 | $4.92M | Sell |
120,557
-146,575
| -55% | -$4.21M | 0.02% | 419 |
|
|
2024
Q1 | $6.82M | Sell |
267,132
-3,027
| -1% | -$47.4K | 0.03% | 385 |
|
|
2023
Q4 | $2.44M | Sell |
270,159
-118,923
| -31% | -$795K | 0.01% | 625 |
|
|
2023
Q3 | $2.48M | Sell |
389,082
-218,428
| -36% | -$1.88M | 0.01% | 552 |
|
|
2023
Q2 | $6.74M | Buy |
607,510
+226,589
| +59% | +$2.84M | 0.04% | 351 |
|
|
2023
Q1 | $5.85M | Buy |
380,921
+63,978
| +20% | +$1.41M | 0.04% | 348 |
|
|
2022
Q4 | $7.03M | Buy |
316,943
+181,861
| +135% | +$2.71M | 0.06% | 299 |
|
|
2022
Q3 | $2.21M | Buy |
135,082
+90,108
| +200% | +$1.72M | 0.02% | 487 |
|
|
2022
Q2 | $653K | Sell |
44,974
-32,853
| -42% | -$489K | 0.01% | 760 |
|
|
2022
Q1 | $1.44M | Buy |
77,827
+13,620
| +21% | +$231K | 0.01% | 701 |
|
|
2021
Q4 | $1.53M | Buy |
64,207
+22,726
| +55% | +$543K | 0.01% | 751 |
|
|
2021
Q3 | $1.02M | Sell |
41,481
-6,715
| -14% | -$146K | 0.01% | 809 |
|
|
2021
Q2 | $1.19M | Sell |
48,196
-12,508
| -21% | -$291K | 0.01% | 824 |
|
|
2021
Q1 | $1.32M | Buy |
+60,704
| New | +$1.49M | 0.01% | 708 |
|
Other funds holding RNAM
Rafferty Asset Management's RNAM Position: Q1 2026 in Review
Rafferty Asset Management sold out of Avidity Biosciences (RNAM) in Q1 2026, closing a stake of 81,533 shares — an estimated $5.88M sold.
Rafferty Asset Management first reported a position in RNAM in Q1 2021 and held it in 20 quarters. The position peaked at $9.16M in Q3 2024. 1 fund tracked by Wall St. Rank holds RNAM as of Q1 2026.
- Rafferty Asset Management reported no remaining Avidity Biosciences position as of Q1 2026 after selling out during the quarter.
- Rafferty Asset Management sold 81,533 Avidity Biosciences shares in Q1 2026, an estimated $5.88M.
- Rafferty Asset Management first reported a position in Avidity Biosciences in Q1 2021 and held it in 20 quarters.
- Rafferty Asset Management's Avidity Biosciences position peaked at $9.16M in Q3 2024.
- 1 fund tracked by Wall St. Rank held Avidity Biosciences as of Q1 2026.
Based on Rafferty Asset Management's 13F filing for Q1 2026, filed 15 May 2026.